Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
The best recommendation on use of Daptomycin-
Was given by Dr. Ralph Corey,MD. Professor of Internal Medicine and Infectious Diseases at the Duke University Medical Center. He also served as the leader of the Ajudication Committee employed by Cubist. This committee had the task of evaluating all the clinical trial data completely blind and completely independent of Cubist staff personnel.He said during his presentation to the Advisory committee--I have
a two year old daufghter with an S. Aureous infection. Guess what treatment he has selected for her????
Didn't take the company long!
Cubist Pharmaceuticals Has Submitted Response to FDA Approvable Letter Received on Friday; FDA Action Anticipated By
RedNova Mon, 27 Mar 2006 1:09 PM PST
Cubist Pharmaceuticals, Inc. (Nasdaq: CBST) today announced that the Company has submitted to the Food & Drug Administration (FDA) an amendment to the sNDA for CUBICIN(R) (daptomycin for injection), in complete response to the FDA Approvable Letter of March 24, 2006.
You are jousting with a well known basher. Suggest you put him on ignore as many have already done.
Boston Globe Article. Good Read.
http://tinyurl.com/l54qc
very well written article. thanks for posting it.
60 Minutes: From Joe Mainstreet to Daddy Warbucks
By Mark Faulk
March 26, 2006
Another week, another tepid news report. This was how I phrased it two days ago, as excitement spread about the 60 Minutes “expose’” that aired tonight:
In other news, CBS is airing a segment on 60 Minutes this Sunday about hedge fund SAC and Gradient Analytics concerning stock manipulation accusations involving Overstock.com. In this writer’s opinion, it will most likely be another “isolated incident” story, just as NBC Dateline turned their “major expose” into a 10 minute segment about a single company, Eagletech Communications, and ignored the larger issue altogether. In fact, I’d be willing to bet that there will be no more than a passing reference to naked short selling at all, and that that will accompanied by a lame joke about the word “naked” and a slightly embarrassed giggle from a female commentator. Any takers? Our only hope is that Patrick Byrne is involved in the segment, because, given more than 30 seconds of air time, he will address the larger issue of fail to delivers and stock counterfeiting. Good for him.
As it turns out, I was being overly optimistic at that. It was indeed just another “isolated incident” story (with one notable exception), although a well-presented one, but they didn’t even mention naked short selling, stock counterfeiting, or fail-to-delivers AT ALL, and the only mention of Overstock was a cursory, “It’s worth noting that Camelback, now known as Gradient, is being sued by another company on charges that parallel the Biovail case.”
In all fairness, the 60 Minutes piece was far superior to the watered-down Dateline whitewash, and it painted a fairly unflattering picture of SAC Hedge Fund owner Steven Cohen as Daddy Warbucks, showing an aerial view of his massive mansion, complete with outdoor hockey rink, on his 14 acre walled estate, and pointing out his $500 million salary from 2005. They also showed him to be as secretive as the hedge fund industry itself. Of course, this is the same man once called by Business Week “The Most Powerful Man on Wall Street You’ve Never Heard of”.
Read the rest of this commentary at:
http://www.faulkingtruth.com/Articles/LettersToEditor/1028.html
The Parallel Universe of the DTCC: “Bits and bytes in book-entry form.”
by Mark Faulk
March 24, 2006
In an article written to convince states and the securities industry to eliminate stock certificates altogether, appropriately entitled “Escaping the Parallel Universe of Paper Certificates”, DTCC Chairman and CEO Jill Considine entered a parallel universe of her own. It was a statement made to underscore an ongoing campaign by the DTCC and SEC to eliminate the only truly tangible proof of stock ownership.
Let’s take a look at Considine’s Cosmic Theory of Parallel Universes. After her “We work in parallel universes all the time” opening statement, she goes on to say:
“In one universe, we’re in a world of high technology with paperless trading and straight-through processing. In this universe, securities are dematerialized. They can be issued, traded, registered, cataloged and stored quickly and electronically. Because they consist of bits and bytes in book-entry form, they’re nearly impossible to steal or destroy. And they can be delivered halfway round the world in seconds.”
Hey, wait a minute. Did I hear that right? Did the Chairman and CEO of the DTCC just say that shares of stock “can be delivered halfway around the world in seconds”? And “they’re nearly impossible to steal or destroy”? That can’t be right. According to the latest Reg SHO list, there are 159 stocks having significant fail to delivers for at least 13 days, twenty-three on the list for over 100 days, and four (Krispy Kreme, Martha Stewart Living, Netflix, and Global Crossing) with significant fail-to-delivers for a whopping 303 days.
But yet, there it is in black and white, or it you prefer, there it is in bits and bytes. Stock “can be delivered halfway around the world in seconds.” Oh yeah, I almost forgot. The securities industry works in parallel universes all the time. In one universe (the one where they want to eliminate paper certificates altogether), they can deliver stock in nanoseconds, but in their parallel universe, they can’t deliver the shares in 303 days (and counting).
While the DTCC and the SIA lobby states to eliminate paper certificates, a shareholders’ task force for CMKM Diamonds (CMKX) has been conducting a stock certificate pull for that company, in an attempt to establish just how many of their shares are real, and how many are simply “bits and bytes in book-entry form”.
To read the rest of this article, and to hear about the 60 Minutes segment (hopefully) dealing with the topic of naked short selling set to air this weekend, go to:
http://www.faulkingtruth.com/Articles/Investing101/1054.html
Approval of a label expansion for Cubicin, an antibiotic marketed by Cubist Pharmaceuticals (nasdaq: CBST - news - people ), is expected by RBC Capital Markets. The FDA will decide whether to allow the bacteria-killing drug to be used as a treatment for bacteremia, or bacteria in the bloodstream, and endocarditis, an inflammation of the inside lining of the heart. "We believe the FDA will likely approve Cubicin with a broad label that will open the door for significantly increased product sales and create substantial lasting competitive advantage," said RBC on March 7. "Robust sales growth and emerging profitability make Cubist a very attractive, lower-risk, small-cap stock."
Sure do. Look at web site for informnation.
Touting is not welcome here.
Thanks fort your post. Needed it to refresh a failing memory!
NewMarket Technology Inc. (OTCBB:NMKT, $0.36)--Chart below-- Traded 6.2 Million shares yesterday (highest trading volume in two years) on a Company press release on strategy of pending spinoffs (see below), valuation discussion and recent research report on NMKT indicating target price of $0.90 (http://www.otclive.com/NMKT_Initiation_Report.pdf).
Trading volume today OVER 2 Million in first 90 minutes.
National exchange listed companies with comparable revenue (and some being unprofitable and growing slower than NMKT) are trading at a Price to Sales ratio of more than 2X Revenue vs. NMKT (profitable and growing rapidly) trading at a Price to Sales ratio of less than 1X Revenue.
NEAR-TERM CATALYSTS FOR NMKT
2005 Annual Report due out in next 9 days (March 31) expected to show 100% revenue growth in 2005 over 2004 and an increase in net income (First three quarters of 2005 showed $1.2 Million in income)
Conference call with potential investors and shareholders to be conducted by the CEO and CFO after CEO returns from trade mission to China (about April 9)
First Quarter, 2006 expected in 55 days (May 15) --Management expects revenue growth forecast for 2006 to be increased
First revenue impact of recent acquisition in Latin America (2005 revenues of $14 Million) will be in First Quarter filing
Public listing of subsidiary technology companies (spinoffs) this year will allow NMKT:
concentrated capital formation to support continued subsidiary growth without dilution of NMKT stock
dividend issues of publicly traded subsidiary stock to NewMarket shareholders
NewMarket profits increased through the monetization of subsidiary stock,
strengthening of the company's balance sheet through the company's ownership of marketable securities.
Broke through 50 Day Moving Average
200 Day Moving Average at $0.38
Under Accumulation
Large Blocks Traded
NewMarket Technology Inc. (OTCBB:NMKT, $0.36)--Chart below-- Traded 6.2 Million shares yesterday (highest trading volume in two years) on a Company press release on strategy of pending spinoffs (see below), valuation discussion and recent research report on NMKT indicating target price of $0.90 (http://www.otclive.com/NMKT_Initiation_Report.pdf).
Trading volume today OVER 2 Million in first 90 minutes.
National exchange listed companies with comparable revenue (and some being unprofitable and growing slower than NMKT) are trading at a Price to Sales ratio of more than 2X Revenue vs. NMKT (profitable and growing rapidly) trading at a Price to Sales ratio of less than 1X Revenue.
NEAR-TERM CATALYSTS FOR NMKT
2005 Annual Report due out in next 9 days (March 31) expected to show 100% revenue growth in 2005 over 2004 and an increase in net income (First three quarters of 2005 showed $1.2 Million in income)
Conference call with potential investors and shareholders to be conducted by the CEO and CFO after CEO returns from trade mission to China (about April 9)
First Quarter, 2006 expected in 55 days (May 15) --Management expects revenue growth forecast for 2006 to be increased
First revenue impact of recent acquisition in Latin America (2005 revenues of $14 Million) will be in First Quarter filing
Public listing of subsidiary technology companies (spinoffs) this year will allow NMKT:
concentrated capital formation to support continued subsidiary growth without dilution of NMKT stock
dividend issues of publicly traded subsidiary stock to NewMarket shareholders
NewMarket profits increased through the monetization of subsidiary stock,
strengthening of the company's balance sheet through the company's ownership of marketable securities.
Broke through 50 Day Moving Average
200 Day Moving Average at $0.38
Under Accumulation
Large Blocks Traded
Billy don't depend upon one investment advisor. If Tobin was so smart he'd be retired but I note he is still scambling like most of us to earn a living.
Why don't you personally take advantage of the current low price and beef up your holdings???
No shares are issued in this PP. Participants have a certificate of their investment. In any event that company is not currently a part of the NMKT family. It is independent and will become a part of NMKT at an appropriate time.
WHY DO I REMEMBER THAT IN ONE NEWS RELEASE ABOUT THE CHINA OPERATION THE COMPANY INDICATED IT WOULD BE FINANCED BY A PRIVATE PLACEMENT?
Merrill report
http://yahoo.reuters.com/stocks/QuoteCompanyNewsArticle.aspx?storyID=urn:newsml: reuters.com:20060306:MTFH89452_2006-03-06_23-27-50_N0613845&symbol=CBST.O&rpc=44
?
Michael W. Bonney
President & Chief Executive Officer
To Our Shareholders:
In 20°4, Cubist executed the most successful IV antibiotic launch in US history as measured by sales revenue. The success of Cubicin@ is a source of great pride for all of us. Cubist is now a com¬mercial biopharmaceutical company, with capabilities from laboratory bench to patient bedside. Our rapid commercial success is compelling evidence that we have built an organization with the skill set and flexibility to navigate significant change.
2°°4 was also a year in which we proved to the marketplace and our shareholders that we are an organization that delivers on our promises. The accomplishments last year-against clearly articu¬lated goals-include the delivery of product revenues within guidance; the filing and acceptance of an MAA to gain approval to market CUBICIN in the European Union; completion of patient enroll¬ment for a groundbreaking Phase 3 infectious endocarditis(IE)/bacteremia trial; filing of an sNDA for approval of an additional bulk daptomycin manufacturing facility; in-licensing of HepeX-BTM, a novel monoclonal antibody product which is in a Phase 2 trial; and promising developments in our drug discovery research program. All of this was accomplished while we delivered significant bal¬ance sheet and net loss improvements.
Many of our activities in 2004, including our successful secondary financing, were designed to secure the base for Cubist. We now have a scalable organization with the controls and discipline in place to meet the needs of the business as we grow.
A year of great change and accomplishment requires the dedicated teamwork of many talented individuals. In 2004 we devoted significant energy to professionalizing many aspects of the ways in which we attract, manage, motivate and reward our employees. Our human resources efforts are focused on attracting the best people available, enabling them to be productive as quickly as possi¬ble, paying them fairly, providing easy access to company and job specific information, and provid¬ing appropriate training and development opportunities. It really all comes down to creating an environment and building a culture that attracts and retains the best talent with the skills and commitment that we need for Cubist to continue to grow and be successful.
¬
I
:
NewMarket Technology will be filing its 2005 Fourth Quarter and Annual Report by the end of this month, March 2006. As previously disclosed, the company expects to report revenue of about $50 Million and profitable (to add to the profit of $1.2 Million for the first three quarters of 2005). After allowing a week to ten days for investors to review the filing (and the return of the CEO, Mr. Philip Verges, from the China Trade Mission), the company will conduct a Conference Call with Mr. Verges and the CFO, Mr. Phil Rauch, to answer questions submitted to LCGroup@mindspring.com.
Separately, there will be a CEO interview appearing in the April 7 issue (Business Services issue) of the Wall Street Transcript (www.twst.com). The Wall Street Transcript is a leading information source for professional investors, money managers, investment brokers and research analysts seeking successful new investment ideas. The Wall Street Transcript conducts in-depth interviews of CEOs with leading public companies, analysts and money managers to give sophisticated investors an unscripted, first-hand perspective that enables them to make informed investment decisions.
First Quarter, 2006 financial results will be filed before the due date of May 15. The CEO will update the company's revenue growth forecast at that time.
dtcc.com/Publications/dtcc/mar05/naked_short_selling.html
Hospital AntiBacterial Market
The Hospital Antibacterial Market Presents New Opportunities for Small Pharmaceutical Companies
RedNova Wed, 15 Mar 2006 1:32 PM PST
Research and Markets (http://www.researchandmarkets.com/reports/c31629) has announced the addition of Antibacterial Drug Resistance: Expanding Opportunities in the Hospital Market to their offering.
CBST: CUBIST PHARMACEUTICALS INC FILES (4) (CBST)
- Mar 14 2006 10:36AM (EDGAR Online)
- http://finance.lycos.com/home/news/story.asp?story=56656605
I strongly doubt your hypothesis. Do you know how many shares Mr Verges and his co-founders now hold????
NEWS ALERT
from The Wall Street Journal
March 14, 2006
Goldman Sachs posted record profit for its fiscal first quarter on strong revenue from its trading and investment-banking divisions. Earnings rose 64% on $10.34 billion in net revenue. Lehman and Bear Stearns report their results later this week.
For more information, see:
http://online.wsj.com/article/SB114210475411795836.html?mod=djemalert
Just a theory of mine. How much of this gross profit was derived from naked shorting?????
I expect there will be little or no news to report while the FDA and CBST work out the details of the labeling to be used on Dapto.As a result the share price should drift-perhaps a bit lower than current price. It is possible,however that due to the unanimous vote of the panel to expand the indications for use that Doctors will increase the use of Dapto in "off label" applications. This could well affect the bottom line and the next financial quarterly report could well hold a pleasant surprise.
Merrill's News Release
Got it exactly right!
Cubist Pharmaceuticals Inc (CBST, $23.44, C-1-9)
Reiterate Buy. Raising PT from $30 to $33. FDA Panel Positive on
Cubicin. The FDA panel voted 9-0 in favor of expanding Cubicin's label to
include Staph aureus bacteremia & 5-4 in favor of expanding the label to
include infective endocarditis. Comments made by FDA participants, lead
us to believe that FDA may be supportive of the sNDA for Cubicin,
potentially with a broader label. We think it is possible that the label may
indicate Cubicin for the treatment of complicated and uncomplicated
bacteremia, without noting suspected or definite endocarditis. This would
be a broader label than CBST requested
Wise move.
Post your thoughts on your stock picks on their board.
NewMarket Technology, Inc. (NMKT) SqueezeTrigger Price is $0.43
Thursday March 9, 9:26 am ET
Approximately 19.5 Million Shares Shorted since January 2005 According to Buyins.net Research Report
DALLAS--(BUSINESS WIRE)--March 9, 2006--BUYINS.NET, www.buyins.net, is reiterating coverage of NewMarket Technology, Inc. (OTCBB:NMKT - News) after releasing the latest short sale data to March 2006. From January 2005 to March 2006 approximately 252.9 million total aggregate shares of NMKT have traded for a total dollar value of nearly $108.4 million. The total aggregate number of shares shorted in this time period is approximately 19.5 million shares. The NMKT SqueezeTrigger price of $0.43 is the volume weighted average short price of all short selling in NMKT. A short squeeze is expected to begin when shares of NMKT close above $0.43. To access SqueezeTrigger Prices ahead of potential short squeezes beginning, visit http://buyins.net/squeezetrigger.pdf.
Short
Avg. Dollar
Month Total Volume Short Volume Price Value
------------------------ ------------ ------------ ------- -----------
January '05 15,057,533 1,159,430 $0.65 $749,224
February 16,744,815 1,289,351 $0.62 $797,721
March 16,164,756 1,244,686 $0.54 $667,525
April 12,741,226 981,074 $0.48 $470,916
May 13,820,360 1,064,168 $0.44 $465,573
June 21,706,228 1,671,380 $0.51 $852,404
July 12,175,556 937,518 $0.47 $439,508
August 14,465,750 1,113,863 $0.41 $460,805
September 10,378,287 799,128 $0.39 $308,623
October 17,501,124 1,347,587 $0.39 $525,828
November 14,281,293 1,099,660 $0.37 $404,125
December 17,641,624 1,358,405 $0.34 $455,066
January '06 29,716,456 2,288,167 $0.30 $691,713
February 26,109,716 2,010,448 $0.32 $652,390
March 14,439,207 1,111,819 $0.36 $404,702
Total: 252,943,931 19,476,683 $0.43 $8,346,124
short volume is approximated using a proprietary algorithm.
average short price is calculated using a volume weighted average short price.
short volume is the total short trade volume and does not account for covers.
NMKT On OTCBB Naked Short Threshold List
On List Off List # Days
April 8, 2005 April 25, 2005 12
NewMarket Technology, Inc. has been on the OTCBB Naked Short Threshold list 1 time. Regulation SHO took effect January 3, 2005, and provides a new regulatory framework governing short selling of securities. It was designed with the objective of simplifying and modernizing short sale regulation and providing controls where they are most needed. At the conclusion of each settlement day, data is provided on securities in which: 1) there are at least 10,000 shares in aggregate failed deliveries for the security for five consecutive settlement days, and 2) these failures constitute at least 0.5% of the issuer's total shares outstanding. SEC Regulation SHO, under the Securities Exchange Act of 1934, mandates that, if a clearing agent has had a fail-to-deliver position for 13 consecutive settlement days, that clearing agent, and the broker/dealer it clears for, must purchase securities to close out its fail to deliver position.
CBST: XOMA Reports 2005 Results; Significant Revenue Growth and Other
Key Milestones Attained in 2005
- Mar 8 2006 6:37PM (BusinessWire)
- http://finance.lycos.com/home/news/story.asp?story=56499892